Iron deficiency without anemia is a common feature of moderate-to-severe atopic dermatitis (AD), according to a study published in Nutrients. A recently approved injectable eczema drug provides quick ...

Delayed remission with advanced therapies in IBD is not associated with worse 1-year clinical or endoscopic outcomes.

A new analysis highlights differential long-term drug survival of commonly used biologics in psoriasis to guide treatment ...

A real world systematic review and meta-analysis found tildrakizumab improved plaque psoriasis severity and quality of life ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and greater patient access to advanced therapies. The shift from conventional ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...

Khaberni - A medical study has revealed promising results in treating moderate to severe psoriasis, one of the most ...

Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...

MONTREAL, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with ulcerative colitis (UC). Canada’s Drug Agency (CDA-AMC) has ...

Risankizumab [Skyrizi] is the first inhibitor of the p19 subunit of interleukin (IL) 23 approved for the treatment of moderate-to-severe Crohn's disease (CD). Although clinical trials and few ...

The IL-23 inhibitor risankizumab proved to be safe and efficacious after 52 weeks of treatment in patients with palmoplantar psoriasis. Results from the randomized phase 3b study appear in the Journal ...

"Ulcerative colitis is a chronic, unpredictable and sometimes debilitating disease, and people living with the condition need sustained symptom relief," said Edouard Louis, M.D., Ph.D., professor and ...